Free Trial

Nektar Therapeutics (NKTR) Competitors

Nektar Therapeutics logo
$40.18 +4.20 (+11.67%)
Closing price 04:00 PM Eastern
Extended Trading
$40.40 +0.22 (+0.55%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NKTR vs. PCRX, OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMY

Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry.

Nektar Therapeutics vs. Its Competitors

Nektar Therapeutics (NASDAQ:NKTR) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.3% of Nektar Therapeutics shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$74.93M10.20-$118.96M-$8.80-4.57
Pacira BioSciences$700.97M1.70-$99.56M-$2.78-9.51

In the previous week, Nektar Therapeutics had 6 more articles in the media than Pacira BioSciences. MarketBeat recorded 14 mentions for Nektar Therapeutics and 8 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.41 beat Nektar Therapeutics' score of 0.44 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nektar Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Pacira BioSciences
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nektar Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Nektar Therapeutics presently has a consensus price target of $88.33, suggesting a potential upside of 119.84%. Pacira BioSciences has a consensus price target of $30.83, suggesting a potential upside of 16.57%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nektar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Pacira BioSciences
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Pacira BioSciences has a net margin of -18.08% compared to Nektar Therapeutics' net margin of -163.17%. Pacira BioSciences' return on equity of 13.29% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nektar Therapeutics-163.17% -631.43% -58.21%
Pacira BioSciences -18.08%13.29%6.61%

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKTR vs. The Competition

MetricNektar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$764.18M$2.64B$5.77B$9.92B
Dividend YieldN/A49.35%6.67%4.52%
P/E Ratio-4.5723.0375.6026.67
Price / Sales10.20697.71549.81211.80
Price / CashN/A169.7737.1158.92
Price / Book8.135.5011.446.09
Net Income-$118.96M$32.95M$3.28B$266.14M
7 Day Performance34.56%2.69%0.84%0.28%
1 Month Performance78.10%7.87%7.15%4.14%
1 Year Performance137.05%0.79%59.66%23.93%

Nektar Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTR
Nektar Therapeutics
4.1461 of 5 stars
$40.18
+11.7%
$88.33
+119.8%
+93.4%$764.18M$74.93M-4.57220News Coverage
PCRX
Pacira BioSciences
3.1422 of 5 stars
$26.65
+2.5%
$30.83
+15.7%
+76.6%$1.20B$700.97M-9.59720News Coverage
Positive News
OMER
Omeros
3.9853 of 5 stars
$4.38
-0.1%
$18.00
+311.4%
+3.5%$297.08MN/A-2.07210Analyst Forecast
ASMB
Assembly Biosciences
3.3175 of 5 stars
$25.64
+0.1%
$38.67
+50.8%
+40.4%$196.66M$33.25M-4.59100Short Interest ↑
CPIX
Cumberland Pharmaceuticals
0.8189 of 5 stars
$3.45
+1.5%
N/A+185.9%$51.61M$42.07M-15.6880Positive News
LLY
Eli Lilly and Company
5 of 5 stars
$736.71
+0.1%
$950.17
+29.0%
-21.6%$697.38B$53.26B48.1647,000Trending News
JNJ
Johnson & Johnson
4.6281 of 5 stars
$176.58
+0.1%
$176.29
-0.2%
+6.8%$425.28B$90.63B18.89138,100Positive News
ABBV
AbbVie
4.6803 of 5 stars
$209.13
+0.4%
$214.95
+2.8%
+8.0%$369.57B$56.33B99.6255,000Trending News
Dividend Announcement
MRK
Merck & Co., Inc.
4.9978 of 5 stars
$84.14
-1.0%
$107.44
+27.7%
-27.5%$210.17B$64.17B12.9675,000Positive News
PFE
Pfizer
4.9285 of 5 stars
$24.92
0.0%
$28.12
+12.9%
-13.7%$141.66B$63.83B13.2581,000Trending News
BMY
Bristol Myers Squibb
4.8903 of 5 stars
$47.32
+0.2%
$56.38
+19.1%
-6.6%$96.34B$47.70B19.0834,100Positive News
Insider Trade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners